FGC
ASND icon

Financial Gravity Companies’s Ascendis Pharma A/S ASND Stock Holding History

Financial Gravity Companies’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		$0 Buy
+2
New +$126 ﹤0.01% 1363
2018
Q1 		$0 Buy
+3
New +$169 ﹤0.01% 1396

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Financial Gravity Companies's ASND Position: Q4 2018 in Review

Financial Gravity Companies opened a new position in Ascendis Pharma A/S (ASND) in Q4 2018: 2 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1363 among its holdings. This is a return to the name: Financial Gravity Companies previously reported a position in ASND as recently as Q1 2018.

Financial Gravity Companies first reported a position in ASND in Q1 2018 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold ASND as of Q4 2018.

  • Financial Gravity Companies held 2 shares of Ascendis Pharma A/S worth $0 as of Q4 2018.
  • Ascendis Pharma A/S was a new Financial Gravity Companies position in Q4 2018.
  • Ascendis Pharma A/S made up ﹤0.01% of Financial Gravity Companies's portfolio in Q4 2018, its #1363 holding.
  • Financial Gravity Companies first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2018.

Based on Financial Gravity Companies's 13F filing for Q4 2018, filed 4 Feb 2019.